Oct 22, 2020

Spotlight on rare NMOSD: Chord launches with $16m Series A round

Allie Nawrat covers OMEGA's funding and stresses the necessity of CHORD Therapeutics' work in an article in Pharmaceutical Technology

"Omega Funds has backed Chord Therapeutics with $16m Series A funding. This money will be used to advance CRD1, Chord’s lead candidate, into Phase II proof-of-concept studies for NMOSD. How could CRD1 improve the treatment of patients with these rare conditions?"

Read more HERE